ifosfamide has been researched along with Disease Exacerbation in 118 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation." | 9.20 | A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015) |
| "Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role." | 9.19 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014) |
| "To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma." | 9.14 | Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009) |
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 9.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate." | 9.11 | ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004) |
| "Our aim was to determine the efficacy of ifosfamide, mesna, and interferon alpha combination therapy in malignant mesothelioma (MM) patients." | 9.11 | Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. ( Altinbas, M; Coskun, HS; Ekici, E; Er, O; Eser, B; Gulmez, I; Kaplan, B; Ozesmi, M; Ozkan, M, 2004) |
| "The combination of Ifosfamide and L-Dauno was found to be a highly active chemotherapy regimen for first-line treatment of soft tissue sarcoma." | 9.11 | Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. ( Deckert, PM; Hütter, G; Keilholz, U; Schmittel, A; Siehl, JM; Szelényi, H; Thiel, E, 2005) |
| "The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis." | 9.11 | A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 9.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 9.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas." | 9.10 | Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. ( Boni, C; Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T; Marrocco, E; Masci, G; Pagani, O; Tucci, A, 2002) |
| "Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy." | 9.09 | Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 9.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 9.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| "We sought to (1) evaluate the disease-specific survival at 2 and 5 years of patients with dedifferentiated chondrosarcoma; (2) assess the prognostic variables (both patient- and treatment-related), including the use of chemotherapy with ifosfamide, that relate to survivorship; and (3) assess specific toxicities associated with ifosfamide use." | 7.80 | Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? ( Deavers, M; Harun, N; Kawaguchi, S; Lewis, VO; Lin, PP; Sun, T, 2014) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 6.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 6.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma." | 5.35 | Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009) |
| "We examined the clinical significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on the Glutaminase 1 gene (GLS1) expression." | 5.27 | Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression. ( Li, H; Li, X; Sun, XH; Yan, XF; Zhang, SP, 2018) |
| "Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation." | 5.20 | A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015) |
| "Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma." | 5.20 | Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. ( Brennan, B; Brichard, B; Craft, A; Dirksen, U; Gaspar, N; Gelderblom, H; Hjorth, L; Judson, I; Juergens, H; Kruseova, J; Kühne, T; Ladenstein, RL; Le Deley, MC; Le Teuff, G; Marec-Berard, P; Paulussen, M; van den Berg, H; Wheatley, K; Whelan, J, 2015) |
| "Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role." | 5.19 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014) |
| "The aim of this phase II study was to investigate the efficacy and toxicity of combined ifosfamide and cisplatin chemotherapy in patients with recurrent epithelial ovarian cancer (EOC)." | 5.17 | Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer. ( Bae, DS; Choi, CH; Kim, BG; Kim, MK; Kim, TJ; Lee, JW; Lee, YY; Song, T, 2013) |
| "To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma." | 5.14 | Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009) |
| "Patients < or = 30 years with Ewing sarcoma, primitive neuroectodermal tumor or primitive sarcoma of bone were randomly assigned to receive chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin, (VACA) or with these four drugs alternating with ifosfamide and etoposide (VACA-IE)." | 5.12 | Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. ( Bernstein, M; Chen, Z; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, M; Laurie, F; Miser, JS; Tarbell, NJ; Yock, TI, 2006) |
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 5.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "The combination of Ifosfamide and L-Dauno was found to be a highly active chemotherapy regimen for first-line treatment of soft tissue sarcoma." | 5.11 | Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. ( Deckert, PM; Hütter, G; Keilholz, U; Schmittel, A; Siehl, JM; Szelényi, H; Thiel, E, 2005) |
| "Our aim was to determine the efficacy of ifosfamide, mesna, and interferon alpha combination therapy in malignant mesothelioma (MM) patients." | 5.11 | Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia. ( Altinbas, M; Coskun, HS; Ekici, E; Er, O; Eser, B; Gulmez, I; Kaplan, B; Ozesmi, M; Ozkan, M, 2004) |
| "The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis." | 5.11 | A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004) |
| "To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate." | 5.11 | ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004) |
| "The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy." | 5.10 | Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002) |
| "The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone." | 5.10 | Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003) |
| "To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas." | 5.10 | Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. ( Boni, C; Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T; Marrocco, E; Masci, G; Pagani, O; Tucci, A, 2002) |
| "Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy." | 5.09 | Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999) |
| "The aim of this study was to examine the strategy, feasibility and outcome of neo-adjuvant chemotherapy, with doxorubicin and ifosfamide, in adult patients with 'high-risk' soft-tissue sarcomas." | 5.09 | A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. ( Azzarelli, A; Bramwell, VH; Buesa, J; Ezzat, A; Gortzak, E; Kirkpatrick, A; Oosterhuis, JW; Santoro, A; van Coevorden, F; van Geel, AN; van Glabbeke, M; Verweij, J, 2001) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 5.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 5.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| "We sought to (1) evaluate the disease-specific survival at 2 and 5 years of patients with dedifferentiated chondrosarcoma; (2) assess the prognostic variables (both patient- and treatment-related), including the use of chemotherapy with ifosfamide, that relate to survivorship; and (3) assess specific toxicities associated with ifosfamide use." | 3.80 | Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? ( Deavers, M; Harun, N; Kawaguchi, S; Lewis, VO; Lin, PP; Sun, T, 2014) |
| "Disease progression was discovered when the patient got adjuvant epirubicin, ifosfamide, and bevacizumab for 2 cycles." | 3.01 | Perianal rhabdomyosarcoma in an adult: A case report and review of the literature. ( Kong, D; Liu, Y; Wang, X; Yang, N, 2023) |
| "Six patients experienced early disease progression, and four patients died while on treatment." | 2.73 | Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. ( Daniels, S; McTiernan, A; Roylance, R; Seddon, B; Sykes, K; Whelan, J, 2007) |
| "Secondary objectives were time to disease progression, response rates, evaluation of toxicity, disease-related symptoms, World Health Organization performance status (PS), and quality of life (QoL)." | 2.71 | Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. ( Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N, 2003) |
| "Ifosfamide was administered by intravenous infusion over 3 h immediately followed by a 30-min infusion of topotecan." | 2.70 | Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors. ( Grübner, U; Höffken, K; Hoffmann, A; Kath, R; Merkel, U; Schneider, CP, 2002) |
| "Neutropenia was the dose limiting toxicity (G1=6%, G2=11%, G3=10%, G4=7%)." | 2.70 | Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer. ( Camps, C; García, R; Maestu, I; Montalar, J; Morales, S; Segura, A; Torregrosa, D; Vadell, C; Yuste, AL, 2001) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 2.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| " A doubling of the intensity of cyclophosphamide (or ifosfamide equivalent) dosing per cycle between IRS-III and IRS-IV is thought to be a key contributing factor for this improvement." | 2.69 | Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. ( Anderson, JR; Baker, KS; Breneman, JC; Crist, WM; Grier, HE; Link, MP; Maurer, HM; Qualman, SJ; Wiener, ES, 2000) |
| "The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined." | 2.69 | Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kiamouris, C; Kosmidis, P; Papadimitriou, C; Papakostas, P; Pavlidis, N; Sikiotis, K; Skarlos, DV, 2000) |
| "Phlebitis was observed in 15 of 30 patients (50%) who did not have central implantable venous systems." | 2.68 | Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma. ( Amato, S; Barbieri, M; Cuevas, M; Dominguez, M; Lacava, J; Langhi, M; Leone, B; Machiavelli, M; Ortiz, E; Perez, J; Rodriguez, R; Romero Acuña, J; Romero Acuña, L; Romero, A; Sabatini, C; Salvadori, M; Vallejo, C, 1996) |
| " Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion." | 2.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "There were four patients with pineoblastoma, two of whom had a positive familial history." | 2.44 | Trilateral retinoblastoma. ( Antoneli, CB; Arias, VE; Chojniak, MM; Novaes, PE; Ribeiro, Kde C; Sakamoto, LH, 2007) |
| "On multivariate analysis, metastasectomy and objective response or stable disease achieved with first-line chemotherapy were indicators for better overall survival." | 1.51 | Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. ( Cornillie, J; Debiec-Rychter, M; Hompes, D; Langmans, C; Schöffski, P; Sciot, R; van Cann, T; Vandenbempt, I; Wozniak, A, 2019) |
| "However, some patients experience early disease progression." | 1.48 | Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. ( Amaki, J; Asano, N; Choi, I; Ejima, Y; Fukuhara, N; Katayama, N; Kim, SJ; Kim, WS; Ko, YH; Kobayashi, Y; Kubota, N; Maeda, T; Miyazaki, K; Oguchi, M; Saito, B; Shimada, K; Shimoda, E; Soejima, T; Suzuki, R; Terui, Y; Tsukamoto, N; Utsumi, T; Yamaguchi, M, 2018) |
| "From the Danish Testicular Cancer database, we identified all patients who received more than one line of treatment for disseminated disease." | 1.42 | Germ Cell Cancer and Multiple Relapses: Toxicity and Survival. ( Agerbaek, M; Bandak, M; Daugaard, G; Gupta, R; Holm, NV; Kier, MG; Lauritsen, J; Mortensen, MS, 2015) |
| "Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment." | 1.42 | Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas? ( Fan, Z; Guadagnolo, BA; Lewis, VO; Lin, PP; Patel, S, 2015) |
| "Standard treatment of cervical cancer FIGO stage IB1 is a radical hysterectomy with pelvic lymphadenectomy." | 1.42 | Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer. ( Leunen, K; Moerman, P; Neven, P; Salihi, R; Van Limbergen, E; Vergote, I, 2015) |
| "Locally advanced cervical cancer (LACC) is one of the leading health problems of the developing countries." | 1.42 | Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy. ( Boraska Jelavić, T; Hamm, W; Hrepić, D; Petrić Miše, B; Prskalo, T; Strikic, A; Tomić, K; Tomić, S; Vrdoljak, E, 2015) |
| "Teratoid Wilms' tumor is considered by some as a variant of Wilms' tumor containing at least 50% heterologous differentiated tissue." | 1.37 | Teratoid Wilms' tumor: case report of a rare variant that can mimic aggressive biology during chemotherapy. ( Raveesunthornkiet, M; Ruangtrakool, R; Sanpaki, K; Thorner, PS; Treetipsatit, J, 2011) |
| "In relapsed germ cell tumors, salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) is a well-established regimen for patients with favorable features such as a primary testicular tumor and prior complete remission (CR) after the initial chemotherapy." | 1.37 | Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. ( Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS, 2011) |
| "The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma." | 1.35 | Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009) |
| "Hemangiopericytoma (HPC) is an uncommon primary brain tumor with an almost invariable tendency to recur and metastasize." | 1.35 | Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "The patient was diagnosed as having Burkitt's lymphoma (BL) with t(8;14) and t(14;18)." | 1.34 | [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy]. ( Fujishima, M; Fujishima, N; Hirokawa, M; Inomata, M; Kameoka, Y; Saitoh, H; Saitoh, K; Sawada, K; Takahashi, N; Yamanaka, Y; Yoshioka, T, 2007) |
| "Suprasellar germinomas are rare intracranial neoplasms, which mainly occur in children and adolescents and manifest with endocrine symptoms and/or compression syndromes." | 1.34 | [Long-term follow-up of patients with suprasellar germinomas]. ( Bauditz, J; Lochs, H; Ventz, M, 2007) |
| " The purpose of the study was to determine the optimal dosage and the maximal tolerated dose (MTD) of a specified schedule of gemcitabine and ifosfamide." | 1.33 | Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. ( Aschroft, L; Baka, S; Blackhall, F; Buchholz, E; Lorigan, P; Manegold, C; Nagel, S; Schott-von-Römer, K; Thatcher, N, 2006) |
| "Spinal chondrosarcoma are extremely rare and slowly growing tumors." | 1.33 | [Upper cervical chondrosarcoma]. ( Domínguez, CJ; Joly, C; Martín-Ferrer, S; Rimbau, J, 2005) |
| "Although rapid disease progression had resolved transiently, after the start of high-dose chemotherapy, re-progression was apparently observed from day 14." | 1.32 | Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. ( Hosoi, H; Iehara, T; Misawa, A; Sawada, T; Sugimoto, T; Tsuchiya, K, 2003) |
| " Following an uncomplicated pregnancy, a healthy child was born at full term and careful haematological and immunological monitoring has revealed no adverse effects resulting from exposure to rituximab." | 1.32 | Safety of rituximab therapy during the first trimester of pregnancy: a case history. ( Elinder, G; Kimby, E; Sverrisdottir, A, 2004) |
| "A diagnosis of bilateral Wilms tumor was made following percutaneous biopsy of both kidneys; histologic examination confirmed that the tumor was predominantly rhabdomyomatous." | 1.31 | Serum creatine kinase levels parallel the clinical course for rhabdomyomatous Wilms tumor. ( Crooke, MJ; Delahunt, B; Lewis, ME; Pringle, KC; Wiltshire, EJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (15.25) | 18.2507 |
| 2000's | 65 (55.08) | 29.6817 |
| 2010's | 34 (28.81) | 24.3611 |
| 2020's | 1 (0.85) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, N | 1 |
| Kong, D | 1 |
| Wang, X | 1 |
| Liu, Y | 1 |
| Sun, WJ | 1 |
| Zhang, JJ | 1 |
| An, N | 1 |
| Shen, M | 1 |
| Huang, ZX | 1 |
| Li, X | 2 |
| Yamaguchi, M | 2 |
| Suzuki, R | 1 |
| Kim, SJ | 2 |
| Ko, YH | 1 |
| Oguchi, M | 1 |
| Asano, N | 1 |
| Miyazaki, K | 1 |
| Terui, Y | 1 |
| Kubota, N | 1 |
| Maeda, T | 2 |
| Kobayashi, Y | 1 |
| Amaki, J | 1 |
| Soejima, T | 1 |
| Saito, B | 1 |
| Shimoda, E | 1 |
| Fukuhara, N | 1 |
| Tsukamoto, N | 1 |
| Shimada, K | 1 |
| Choi, I | 1 |
| Utsumi, T | 1 |
| Ejima, Y | 1 |
| Kim, WS | 2 |
| Katayama, N | 1 |
| Elsebaie, MAT | 1 |
| Amgad, M | 1 |
| Elkashash, A | 1 |
| Elgebaly, AS | 1 |
| Ashal, GGEL | 1 |
| Shash, E | 1 |
| Elsayed, Z | 1 |
| Zhang, SP | 1 |
| Li, H | 1 |
| Sun, XH | 1 |
| Yan, XF | 1 |
| Kawamoto, K | 1 |
| Suzuki, T | 1 |
| Kasami, T | 1 |
| Kiryu, M | 1 |
| Sone, H | 1 |
| Miyoshi, H | 1 |
| Ohshima, K | 1 |
| Takizawa, J | 1 |
| Langmans, C | 1 |
| Cornillie, J | 1 |
| van Cann, T | 1 |
| Wozniak, A | 1 |
| Hompes, D | 1 |
| Sciot, R | 2 |
| Debiec-Rychter, M | 1 |
| Vandenbempt, I | 1 |
| Schöffski, P | 3 |
| Xu, J | 1 |
| Li, G | 1 |
| Zhu, SM | 1 |
| Cai, QL | 1 |
| Wang, Z | 1 |
| Yang, X | 1 |
| Zhang, HT | 1 |
| Niu, YJ | 1 |
| Cucchiari, D | 1 |
| Bertuzzi, A | 1 |
| Colombo, P | 1 |
| De Sanctis, R | 1 |
| Faucher, E | 1 |
| Fusco, N | 1 |
| Pellegrinelli, A | 1 |
| Arosio, P | 1 |
| Angelini, C | 1 |
| Song, T | 1 |
| Kim, MK | 1 |
| Lee, YY | 1 |
| Choi, CH | 1 |
| Kim, TJ | 1 |
| Lee, JW | 1 |
| Kim, BG | 1 |
| Bae, DS | 1 |
| Kawaguchi, S | 1 |
| Sun, T | 1 |
| Lin, PP | 3 |
| Deavers, M | 1 |
| Harun, N | 1 |
| Lewis, VO | 3 |
| Vakil, K | 1 |
| Raza, A | 1 |
| Zakharova, M | 1 |
| Madlon-Kay, R | 1 |
| Skubitz, K | 1 |
| Patel, M | 1 |
| Judson, I | 3 |
| Verweij, J | 4 |
| Gelderblom, H | 2 |
| Hartmann, JT | 1 |
| Blay, JY | 1 |
| Kerst, JM | 1 |
| Sufliarsky, J | 1 |
| Whelan, J | 3 |
| Hohenberger, P | 1 |
| Krarup-Hansen, A | 1 |
| Alcindor, T | 1 |
| Marreaud, S | 1 |
| Litière, S | 1 |
| Hermans, C | 2 |
| Fisher, C | 1 |
| Hogendoorn, PC | 1 |
| dei Tos, AP | 1 |
| van der Graaf, WT | 1 |
| Sagara, K | 1 |
| Takayoshi, K | 1 |
| Kusumoto, E | 1 |
| Uchino, K | 1 |
| Matsumura, T | 1 |
| Kusaba, H | 1 |
| Momosaki, S | 1 |
| Ikejiri, K | 1 |
| Baba, E | 1 |
| Petrić Miše, B | 1 |
| Boraska Jelavić, T | 1 |
| Strikic, A | 1 |
| Hrepić, D | 1 |
| Tomić, K | 1 |
| Hamm, W | 1 |
| Tomić, S | 1 |
| Prskalo, T | 1 |
| Vrdoljak, E | 1 |
| Hadoux, J | 1 |
| Rey, A | 1 |
| Duvillard, P | 1 |
| Lhommé, C | 1 |
| Balleyguier, C | 1 |
| Haie-Meder, C | 1 |
| Morice, P | 1 |
| Tazi, Y | 1 |
| Leary, A | 1 |
| Larue, C | 1 |
| Pautier, P | 1 |
| Scandurra, G | 1 |
| Scibilia, G | 1 |
| Banna, GL | 2 |
| D'Agate, G | 1 |
| Lipari, H | 1 |
| Gieri, S | 1 |
| Scollo, P | 1 |
| Boni, C | 2 |
| Pagano, M | 1 |
| Baldi, L | 1 |
| Gnoni, R | 1 |
| Braglia, L | 1 |
| Savoldi, L | 1 |
| Zanelli, F | 1 |
| Salihi, R | 1 |
| Leunen, K | 1 |
| Van Limbergen, E | 1 |
| Moerman, P | 1 |
| Neven, P | 1 |
| Vergote, I | 1 |
| Davis, EJ | 1 |
| Chugh, R | 1 |
| Zhao, L | 1 |
| Lucas, DR | 1 |
| Biermann, JS | 1 |
| Zalupski, MM | 1 |
| Feng, M | 1 |
| Wong, SL | 1 |
| Jacobson, J | 1 |
| Zyczynski, L | 1 |
| Reinke, D | 1 |
| Metko, G | 1 |
| Baker, LH | 1 |
| Schuetze, SM | 1 |
| Zwenger, AO | 1 |
| Grosman, G | 1 |
| Iturbe, J | 1 |
| Leone, J | 1 |
| Vallejo, CT | 1 |
| Leone, JP | 1 |
| Verdera, PP | 1 |
| Pérez, JE | 1 |
| Leone, BA | 1 |
| Fan, Z | 1 |
| Patel, S | 1 |
| Guadagnolo, BA | 1 |
| Lauritsen, J | 1 |
| Kier, MG | 1 |
| Mortensen, MS | 1 |
| Bandak, M | 1 |
| Gupta, R | 1 |
| Holm, NV | 1 |
| Agerbaek, M | 1 |
| Daugaard, G | 1 |
| van den Berg, H | 1 |
| Paulussen, M | 1 |
| Le Teuff, G | 1 |
| Dirksen, U | 1 |
| Brennan, B | 1 |
| Ladenstein, RL | 1 |
| Marec-Berard, P | 1 |
| Kruseova, J | 1 |
| Hjorth, L | 1 |
| Kühne, T | 1 |
| Brichard, B | 1 |
| Wheatley, K | 1 |
| Craft, A | 1 |
| Juergens, H | 1 |
| Gaspar, N | 1 |
| Le Deley, MC | 1 |
| Weigel, BJ | 1 |
| Lyden, E | 1 |
| Anderson, JR | 2 |
| Meyer, WH | 1 |
| Parham, DM | 1 |
| Rodeberg, DA | 1 |
| Michalski, JM | 1 |
| Hawkins, DS | 1 |
| Arndt, CA | 1 |
| Yoon, DH | 1 |
| Jeong, SH | 1 |
| Shin, DY | 1 |
| Bae, SH | 1 |
| Hong, J | 1 |
| Park, SK | 1 |
| Yhim, HY | 1 |
| Yang, DH | 1 |
| Lee, H | 1 |
| Kang, HJ | 1 |
| Lee, MH | 1 |
| Eom, HS | 1 |
| Kwak, JY | 1 |
| Lee, JH | 1 |
| Suh, C | 1 |
| Lorch, A | 1 |
| Beyer, J | 1 |
| Chamberlain, MC | 1 |
| Glantz, MJ | 1 |
| Maurel, J | 2 |
| López-Pousa, A | 2 |
| de Las Peñas, R | 2 |
| Fra, J | 2 |
| Martín, J | 1 |
| Cruz, J | 1 |
| Casado, A | 1 |
| Poveda, A | 1 |
| Martínez-Trufero, J | 1 |
| Balañá, C | 1 |
| Gómez, MA | 1 |
| Cubedo, R | 1 |
| Gallego, O | 1 |
| Rubio-Viqueira, B | 1 |
| Rubió, J | 1 |
| Andrés, R | 1 |
| Sevilla, I | 1 |
| de la Cruz, JJ | 1 |
| Del Muro, XG | 1 |
| Buesa, JM | 2 |
| Aoki, T | 1 |
| Mizutani, T | 1 |
| Nojima, K | 1 |
| Takagi, T | 1 |
| Okumura, R | 1 |
| Yuba, Y | 1 |
| Ueba, T | 1 |
| Takahashi, JA | 1 |
| Miyatake, S | 1 |
| Nozaki, K | 1 |
| Taki, W | 1 |
| Matsutani, M | 1 |
| Kato, T | 1 |
| Tanabe, J | 1 |
| Kanemoto, M | 1 |
| Kobayashi, C | 1 |
| Morita, S | 1 |
| Karahashi, T | 1 |
| Lashkari, A | 1 |
| Chow, WA | 1 |
| Valdes, F | 1 |
| Leong, L | 1 |
| Phan, V | 1 |
| Twardowski, P | 1 |
| Kapoor, N | 1 |
| Molina, A | 1 |
| Al-Kadhimi, Z | 1 |
| Frankel, P | 1 |
| Somlo, G | 1 |
| Conrad, AL | 1 |
| Go, RS | 1 |
| Saba, NF | 1 |
| Choi, M | 1 |
| Muller, S | 1 |
| Shin, HJ | 1 |
| Tighiouart, M | 1 |
| Papadimitrakopoulou, VA | 1 |
| El-Naggar, AK | 1 |
| Khuri, FR | 1 |
| Chen, ZG | 1 |
| Shin, DM | 1 |
| Yamada, N | 1 |
| Hata, M | 1 |
| Ohyama, H | 1 |
| Yamanegi, K | 1 |
| Kogoe, N | 1 |
| Nakasho, K | 1 |
| Futani, H | 1 |
| Okamura, H | 1 |
| Terada, N | 1 |
| Kasper, B | 1 |
| Schmitt, T | 1 |
| Wuchter, P | 1 |
| Ho, AD | 1 |
| Egerer, G | 2 |
| Fischer, L | 1 |
| Korfel, A | 1 |
| Pfeiffer, S | 1 |
| Kiewe, P | 1 |
| Volk, HD | 1 |
| Cakiroglu, H | 1 |
| Widmann, T | 1 |
| Thiel, E | 2 |
| Specenier, PM | 1 |
| Van Den Brande, J | 1 |
| Schrijvers, D | 1 |
| Huizing, MT | 1 |
| Altintas, S | 1 |
| Dyck, J | 1 |
| Van Den Weyngaert, D | 1 |
| Van Laer, C | 1 |
| Vermorken, JB | 1 |
| McCulloch, T | 1 |
| Prayle, A | 1 |
| Lunn, A | 1 |
| Watson, AR | 1 |
| Cereda, S | 1 |
| Reni, M | 1 |
| Rognone, A | 1 |
| Fugazza, C | 1 |
| Ghidini, M | 1 |
| Ceraulo, D | 1 |
| Brioschi, M | 1 |
| Nicoletti, R | 1 |
| Villa, E | 1 |
| Vello Román, A | 1 |
| Samprón Rodríguez, M | 1 |
| Pazos Arias, B | 1 |
| Romero Reinoso, C | 1 |
| Peteiro Cancelo, A | 1 |
| Patrij, K | 1 |
| Reiser, M | 1 |
| Wätzel, L | 1 |
| Pels, H | 1 |
| Kowoll, A | 1 |
| Herrlinger, U | 1 |
| Engert, A | 1 |
| Linnebank, M | 1 |
| Schackert, G | 1 |
| Vogt-Schaden, M | 1 |
| Lamprecht, M | 1 |
| Batchelor, TT | 1 |
| Schlegel, U | 1 |
| Schmidt-Wolf, IG | 1 |
| Park, S | 1 |
| Lee, S | 1 |
| Lee, J | 1 |
| Park, SH | 1 |
| Park, JO | 1 |
| Kang, WK | 1 |
| Park, YS | 1 |
| Lim, HY | 1 |
| Treetipsatit, J | 1 |
| Raveesunthornkiet, M | 1 |
| Ruangtrakool, R | 1 |
| Sanpaki, K | 1 |
| Thorner, PS | 1 |
| Sugimoto, K | 1 |
| Ideguchi, M | 1 |
| Sadahiro, H | 1 |
| Yoshikawa, K | 1 |
| Goto, H | 1 |
| Nomura, S | 1 |
| Fujii, M | 1 |
| Suzuki, M | 1 |
| Hervonen, P | 1 |
| Lehtinen, T | 1 |
| Tammela, TL | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| van Oosterom, AT | 1 |
| Mouridsen, HT | 1 |
| Nielsen, OS | 1 |
| Dombernowsky, P | 1 |
| Krzemieniecki, K | 1 |
| Svancarova, L | 1 |
| Spooner, D | 1 |
| Van Glabbeke, M | 2 |
| Misawa, A | 1 |
| Hosoi, H | 1 |
| Tsuchiya, K | 1 |
| Iehara, T | 1 |
| Sawada, T | 1 |
| Sugimoto, T | 1 |
| Gebbia, V | 2 |
| Galetta, D | 2 |
| Caruso, M | 1 |
| Verderame, F | 1 |
| Pezzella, G | 1 |
| Valdesi, M | 1 |
| Borsellino, N | 1 |
| Pandolfo, G | 1 |
| Durini, E | 1 |
| Rinaldi, M | 1 |
| Loizzi, M | 1 |
| Gebbia, N | 2 |
| Valenza, R | 1 |
| Tirrito, ML | 1 |
| Varvara, F | 1 |
| Colucci, G | 2 |
| Grier, HE | 3 |
| Krailo, MD | 1 |
| Tarbell, NJ | 2 |
| Link, MP | 2 |
| Fryer, CJ | 2 |
| Pritchard, DJ | 1 |
| Gebhardt, MC | 2 |
| Dickman, PS | 1 |
| Perlman, EJ | 1 |
| Meyers, PA | 2 |
| Donaldson, SS | 2 |
| Moore, S | 1 |
| Rausen, AR | 1 |
| Vietti, TJ | 1 |
| Miser, JS | 2 |
| Danson, S | 1 |
| Middleton, MR | 1 |
| O'Byrne, KJ | 1 |
| Clemons, M | 1 |
| Ranson, M | 1 |
| Hassan, J | 1 |
| Anderson, H | 1 |
| Burt, PA | 1 |
| Fairve-Finn, C | 1 |
| Stout, R | 1 |
| Dowd, I | 1 |
| Ashcroft, L | 1 |
| Beresford, C | 1 |
| Thatcher, N | 3 |
| Alberola, V | 1 |
| Camps, C | 2 |
| Provencio, M | 2 |
| Isla, D | 1 |
| Rosell, R | 1 |
| Vadell, C | 2 |
| Bover, I | 1 |
| Ruiz-Casado, A | 1 |
| Azagra, P | 1 |
| Jiménez, U | 1 |
| González-Larriba, JL | 1 |
| Diz, P | 1 |
| Cardenal, F | 1 |
| Artal, A | 1 |
| Carrato, A | 1 |
| Morales, S | 2 |
| Sanchez, JJ | 1 |
| Felip, E | 1 |
| López-Vivanco, G | 1 |
| Kolb, EA | 1 |
| Kushner, BH | 1 |
| Gorlick, R | 1 |
| Laverdiere, C | 1 |
| Healey, JH | 1 |
| LaQuaglia, MP | 1 |
| Huvos, AG | 1 |
| Qin, J | 1 |
| Vu, HT | 1 |
| Wexler, L | 1 |
| Wolden, S | 1 |
| Briasoulis, E | 2 |
| Pavlidis, N | 2 |
| Terret, C | 1 |
| Bauer, J | 1 |
| Fiedler, W | 1 |
| Raoul, JL | 1 |
| Hess, D | 1 |
| Selvais, R | 1 |
| Lacombe, D | 2 |
| Bachmann, P | 2 |
| Fumoleau, P | 2 |
| Davidson, KL | 1 |
| Devaney, MB | 1 |
| Tighe, JE | 1 |
| Rogers, SY | 1 |
| Dunlop, DJ | 1 |
| Mackie, MJ | 1 |
| Thomas, RV | 1 |
| Johnson, PR | 1 |
| Giaccone, G | 2 |
| Smit, EF | 1 |
| de Jonge, M | 1 |
| Dansin, E | 1 |
| Ardizzoni, A | 1 |
| Douillard, JY | 1 |
| Spaeth, D | 1 |
| Baron, B | 1 |
| Kimby, E | 1 |
| Sverrisdottir, A | 1 |
| Elinder, G | 1 |
| Patel, SR | 1 |
| Papadopolous, N | 1 |
| Raymond, AK | 1 |
| Donato, M | 1 |
| Seong, CM | 1 |
| Yasko, AW | 1 |
| Champlin, R | 1 |
| Benjamin, RS | 1 |
| Jerkeman, M | 1 |
| Leppä, S | 1 |
| Kvaløy, S | 1 |
| Holte, H | 1 |
| Van der Mieren, G | 1 |
| Willems, S | 1 |
| Dumez, H | 1 |
| Van Oosterom, A | 1 |
| Flameng, W | 1 |
| Herijgers, P | 1 |
| Kawaguchi, T | 1 |
| Kumabe, T | 1 |
| Watanabe, M | 1 |
| Tominaga, T | 1 |
| Altundag, K | 1 |
| Aksoy, S | 1 |
| Gullu, I | 1 |
| Altundag, O | 1 |
| Ozyar, E | 1 |
| Yalcin, S | 1 |
| Cengiz, M | 1 |
| Akyol, F | 1 |
| Altinbas, M | 1 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Coskun, HS | 1 |
| Gulmez, I | 1 |
| Ekici, E | 1 |
| Kaplan, B | 1 |
| Eser, B | 1 |
| Ozesmi, M | 1 |
| Nomura, E | 1 |
| Isoda, K | 1 |
| Yamanaka, K | 1 |
| Hakamada, A | 1 |
| Mizutani, H | 1 |
| Siehl, JM | 1 |
| Schmittel, A | 1 |
| Hütter, G | 1 |
| Deckert, PM | 1 |
| Szelényi, H | 1 |
| Keilholz, U | 1 |
| Domínguez, CJ | 1 |
| Martín-Ferrer, S | 1 |
| Rimbau, J | 1 |
| Joly, C | 1 |
| Antoneli, CB | 1 |
| Ribeiro, Kde C | 1 |
| Sakamoto, LH | 1 |
| Chojniak, MM | 1 |
| Novaes, PE | 1 |
| Arias, VE | 1 |
| Indolfi, P | 1 |
| Bisogno, G | 1 |
| Casale, F | 1 |
| Cecchetto, G | 1 |
| De Salvo, G | 1 |
| Ferrari, A | 1 |
| Donfrancesco, A | 1 |
| Donofrio, V | 1 |
| Martone, A | 1 |
| Di Martino, M | 1 |
| Di Tullio, MT | 1 |
| Losa, R | 1 |
| Sierra, M | 1 |
| Goitia, A | 1 |
| Uña, E | 1 |
| Nadal, R | 1 |
| Del Muro, JG | 1 |
| Gión, M | 1 |
| Escudero, P | 1 |
| Esteban, E | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Baka, S | 1 |
| Manegold, C | 2 |
| Buchholz, E | 2 |
| Schott-von-Römer, K | 1 |
| Lorigan, P | 1 |
| Nagel, S | 1 |
| Blackhall, F | 1 |
| Aschroft, L | 1 |
| Hiraki, A | 1 |
| Murakami, T | 1 |
| Aoe, K | 1 |
| Matsuda, E | 1 |
| Uemori, Y | 1 |
| Ueoka, H | 1 |
| Yock, TI | 1 |
| Krailo, M | 1 |
| Chen, Z | 1 |
| Bernstein, M | 1 |
| Laurie, F | 1 |
| Pohl, G | 1 |
| Krajnik, G | 1 |
| Malayeri, R | 1 |
| Müller, RM | 1 |
| Klepetko, W | 1 |
| Eckersberger, F | 1 |
| Schäfer-Prokop, C | 1 |
| Pokrajac, B | 1 |
| Schmeikal, S | 1 |
| Maier, A | 1 |
| Ambrosch, G | 1 |
| Woltsche, M | 1 |
| Minar, W | 1 |
| Pirker, R | 1 |
| Classen, CF | 1 |
| Warmuth-Metz, M | 1 |
| Papke, K | 1 |
| Trotter, A | 1 |
| Wolff, JE | 1 |
| Wagner, S | 1 |
| De Giorgi, U | 1 |
| Ferrari, B | 1 |
| Castagna, L | 1 |
| Alloisio, M | 1 |
| Marangolo, M | 2 |
| Rosti, G | 2 |
| Santoro, A | 2 |
| Williams, KM | 1 |
| Higman, MA | 1 |
| Chen, AR | 1 |
| Schwartz, CL | 1 |
| Wharam, M | 1 |
| Colombani, P | 1 |
| Arceci, RJ | 1 |
| Schlondorff, JS | 1 |
| Mendez, GP | 1 |
| Rennke, HG | 1 |
| Magee, CC | 1 |
| Pilz, L | 1 |
| Drings, P | 1 |
| Fujishima, N | 1 |
| Fujishima, M | 1 |
| Inomata, M | 1 |
| Yamanaka, Y | 1 |
| Saitoh, K | 1 |
| Kameoka, Y | 1 |
| Yoshioka, T | 1 |
| Saitoh, H | 1 |
| Takahashi, N | 1 |
| Hirokawa, M | 1 |
| Sawada, K | 1 |
| Roylance, R | 1 |
| Seddon, B | 1 |
| McTiernan, A | 1 |
| Sykes, K | 1 |
| Daniels, S | 1 |
| Piantedosi, FV | 1 |
| Caputo, F | 1 |
| Mazzarella, G | 1 |
| Gilli, M | 1 |
| Pontillo, A | 1 |
| D'Agostino, D | 1 |
| Campbell, S | 1 |
| Marsico, SA | 1 |
| Bianco, A | 1 |
| Bauditz, J | 1 |
| Lochs, H | 1 |
| Ventz, M | 1 |
| Tascilar, M | 1 |
| Loos, WJ | 1 |
| Seynaeve, C | 1 |
| Sleijfer, S | 1 |
| Ciaudo, M | 1 |
| Chauvenet, L | 1 |
| Audouin, J | 1 |
| Rossert, J | 1 |
| Favier, R | 1 |
| Horellou, MH | 1 |
| Bernadou, A | 1 |
| Samama, M | 1 |
| Stamatoullas, A | 2 |
| Fruchart, C | 1 |
| Bastit, D | 1 |
| Boulet, D | 1 |
| Moncondult, M | 1 |
| Piguet, H | 1 |
| Tilly, H | 1 |
| Stein, ME | 1 |
| Ruff, P | 1 |
| Weaving, A | 1 |
| Fried, J | 1 |
| Bezwoda, WR | 1 |
| Scagliotti, GV | 1 |
| Ricardi, U | 1 |
| Crinó, L | 1 |
| Maranzano, E | 1 |
| De Marinis, F | 1 |
| Morandi, MG | 1 |
| Meacci, L | 1 |
| Emiliani, E | 1 |
| Figoli, F | 1 |
| Bolzicco, G | 1 |
| Masiero, P | 1 |
| Gentile, A | 1 |
| Tonato, M | 1 |
| Postmus, PE | 1 |
| Scagliotti, G | 1 |
| Groen, HJ | 1 |
| Gozzelino, F | 1 |
| Burghouts, JT | 1 |
| Curran, D | 1 |
| Sahmoud, T | 2 |
| Kirkpatrick, A | 2 |
| Splinter, TA | 1 |
| Vallejo, C | 1 |
| Romero, A | 1 |
| Perez, J | 1 |
| Cuevas, M | 1 |
| Lacava, J | 1 |
| Sabatini, C | 1 |
| Dominguez, M | 1 |
| Rodriguez, R | 1 |
| Barbieri, M | 1 |
| Romero Acuña, L | 1 |
| Romero Acuña, J | 1 |
| Langhi, M | 1 |
| Amato, S | 1 |
| Salvadori, M | 1 |
| Ortiz, E | 1 |
| Machiavelli, M | 1 |
| Leone, B | 1 |
| Sanson, M | 1 |
| Ameri, A | 1 |
| Monjour, A | 1 |
| Ronchin, P | 1 |
| Poisson, M | 1 |
| Delattre, JY | 1 |
| Pronzato, P | 2 |
| Vigani, A | 2 |
| Pensa, F | 2 |
| Vanoli, M | 1 |
| Tani, F | 1 |
| Vaira, F | 2 |
| Riccardi, F | 1 |
| Cariello, S | 1 |
| Kaye, SB | 1 |
| Mead, GM | 1 |
| Fossa, S | 1 |
| Cullen, M | 1 |
| deWit, R | 1 |
| Bodrogi, I | 1 |
| van Groeningen, C | 1 |
| Sylvester, R | 1 |
| Collette, L | 1 |
| Stenning, S | 1 |
| De Prijck, L | 1 |
| Lallemand, E | 1 |
| deMulder, P | 1 |
| Jhanwar-Uniyal, M | 1 |
| Gulati, SC | 1 |
| Urban, C | 1 |
| Benesch, M | 1 |
| Pakisch, B | 1 |
| Lackner, H | 1 |
| Kerbl, R | 1 |
| Schwinger, W | 1 |
| Oberbauer, R | 1 |
| Polyzos, A | 1 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Petrikos, G | 1 |
| Giannikos, L | 1 |
| Kalahanis, N | 1 |
| Papadopoulos, O | 1 |
| Christodoulou, K | 1 |
| Giannakopoulos, K | 1 |
| Veslemes, M | 1 |
| Katsilambros, N | 1 |
| Paulsen, F | 1 |
| Hoffmann, W | 1 |
| Becker, G | 1 |
| Belka, C | 1 |
| Weinmann, M | 1 |
| Classen, J | 1 |
| Kortmann, RD | 1 |
| Bamberg, M | 1 |
| Shamash, J | 1 |
| Oliver, RT | 1 |
| Ong, J | 1 |
| Raja, M | 1 |
| Edmonds, P | 1 |
| Gallagher, CJ | 1 |
| Ostrowski, MJ | 1 |
| LeVay, J | 1 |
| Williams, M | 1 |
| Tognoni, A | 1 |
| Cadenotti, L | 1 |
| Bancalari, L | 1 |
| Cordani, S | 1 |
| Maggiani, R | 1 |
| Canessa, PA | 1 |
| Huuhtanen, RL | 1 |
| Wiklund, TA | 1 |
| Blomqvist, CP | 1 |
| Böhling, TO | 1 |
| Virolainen, MJ | 1 |
| Tribukait, B | 1 |
| Andersson, LC | 1 |
| Lobo, F | 1 |
| Frau, A | 1 |
| Barnadas, A | 1 |
| Méndez, M | 1 |
| Lizón, J | 1 |
| Albistur, JJ | 1 |
| Martínez, P | 1 |
| Sánchez, MJ | 1 |
| Constenla, M | 1 |
| Estévez, LG | 1 |
| Fossella, FV | 2 |
| DeVore, R | 1 |
| Kerr, RN | 1 |
| Crawford, J | 1 |
| Natale, RR | 1 |
| Dunphy, F | 1 |
| Kalman, L | 1 |
| Miller, V | 1 |
| Lee, JS | 1 |
| Moore, M | 1 |
| Gandara, D | 1 |
| Karp, D | 1 |
| Vokes, E | 1 |
| Kris, M | 1 |
| Kim, Y | 1 |
| Gamza, F | 1 |
| Hammershaimb, L | 1 |
| Baker, KS | 1 |
| Qualman, SJ | 1 |
| Maurer, HM | 1 |
| Breneman, JC | 1 |
| Wiener, ES | 1 |
| Crist, WM | 1 |
| Aravantinos, G | 2 |
| Dimopoulos, MA | 2 |
| Kosmidis, P | 1 |
| Bafaloukos, D | 2 |
| Papadimitriou, C | 1 |
| Kiamouris, C | 1 |
| Sikiotis, K | 1 |
| Papakostas, P | 1 |
| Skarlos, DV | 1 |
| Mullier, J | 1 |
| Beauvois, S | 1 |
| Gebhart, M | 1 |
| Roelandts, M | 1 |
| Van Houtte, P | 1 |
| Gortzak, E | 1 |
| Azzarelli, A | 1 |
| Buesa, J | 1 |
| Bramwell, VH | 1 |
| van Coevorden, F | 1 |
| van Geel, AN | 1 |
| Ezzat, A | 1 |
| Oosterhuis, JW | 1 |
| Delahunt, B | 1 |
| Lewis, ME | 1 |
| Pringle, KC | 1 |
| Wiltshire, EJ | 1 |
| Crooke, MJ | 1 |
| Montalar, J | 1 |
| Maestu, I | 1 |
| García, R | 1 |
| Yuste, AL | 1 |
| Torregrosa, D | 1 |
| Segura, A | 1 |
| Köstler, WJ | 1 |
| Brodowicz, T | 1 |
| Attems, Y | 1 |
| Hejna, M | 1 |
| Tomek, S | 1 |
| Amann, G | 1 |
| Fiebiger, WC | 1 |
| Wiltschke, CH | 1 |
| Krainer, M | 1 |
| Zielinski, CC | 1 |
| Fermé, C | 1 |
| Mounier, N | 1 |
| Diviné, M | 1 |
| Brice, P | 1 |
| Reman, O | 1 |
| Voillat, L | 1 |
| Jaubert, J | 1 |
| Lederlin, P | 1 |
| Colin, P | 1 |
| Berger, F | 1 |
| Salles, G | 1 |
| De Pas, T | 1 |
| Curigliano, G | 1 |
| Masci, G | 1 |
| Catania, C | 1 |
| Comandone, A | 1 |
| Tucci, A | 1 |
| Pagani, O | 1 |
| Marrocco, E | 1 |
| de Braud, F | 1 |
| Hanna, NH | 1 |
| Sandier, AB | 1 |
| Loehrer, PJ | 1 |
| Ansari, R | 1 |
| Jung, SH | 1 |
| Lane, K | 1 |
| Einhorn, LH | 1 |
| Seo, JH | 1 |
| Whang, YM | 1 |
| Kim, BS | 1 |
| Choi, CW | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Goo, BH | 1 |
| Calderoni, A | 1 |
| von Briel, C | 1 |
| Aebi, S | 1 |
| Solenthaler, M | 1 |
| Betticher, DC | 1 |
| Papadimitriou, CA | 1 |
| Sarris, K | 1 |
| Kalofonos, C | 1 |
| Gika, D | 1 |
| Gourgoulis, GM | 1 |
| Efstathiou, E | 1 |
| Skarlos, D | 1 |
| Schneider, CP | 1 |
| Merkel, U | 1 |
| Grübner, U | 1 |
| Kath, R | 1 |
| Höffken, K | 1 |
| Hoffmann, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma[NCT00061984] | Phase 3 | 455 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)[NCT02793050] | 510 participants (Actual) | Observational | 2016-06-15 | Completed | |||
| RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.[NCT03375437] | 376 participants (Actual) | Interventional | 2018-02-15 | Active, not recruiting | |||
| PEI REGIMEN: A THERAPEUTIC OPTION IN SMALL CELL LUNG CANCER? A MONOINSTITUTIONAL EXPERIENCE OF 46 CONSECUTIVE CASES[NCT02324296] | 46 participants (Actual) | Observational | 1998-12-31 | Completed | |||
| Prospective Study for the Validation of the Genetic Signature 354849 to Predict the Response to Standard Treatment in Patients With Locally Advanced Cervical Cancer[NCT04067882] | 189 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma[NCT00987636] | Phase 3 | 907 participants (Actual) | Interventional | 2009-10-01 | Completed | ||
| ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)[NCT03840772] | Phase 2 | 16 participants (Anticipated) | Interventional | 2019-07-17 | Recruiting | ||
| A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153] | Phase 2 | 41 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma[NCT00339898] | 414 participants (Actual) | Observational | 2004-03-12 | Completed | |||
| A Phase 1, Open-Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Combined Oral C-Met/ALK Inhibitor (PF-02341066) and Pan-Her Inhibitor (PF-0299804) in Patients With Advanced Non-Small Cell Lung Cancer[NCT01441128] | Phase 1 | 20 participants (Actual) | Interventional | 2011-09-01 | Terminated | ||
| Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Pancreatic Cancer[NCT00005053] | Phase 2 | 35 participants (Actual) | Interventional | 1999-12-31 | Completed | ||
| Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer[NCT00005055] | Phase 2 | 39 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC[NCT00923273] | Phase 1/Phase 2 | 42 participants (Actual) | Interventional | 2008-02-29 | Terminated (stopped due to Premature closure - investigator left the National Institutes of Health.) | ||
| A Study on the Efficacy and Safety of Anlotinib Combined With Docetaxel in the Treatment of Wild-type Advanced Non-squamous Non Small Cell Lung Cancer Patients With Progress After Immunotherapy Plus Chemotherapy as First-line Treatment[NCT04619537] | Phase 2 | 42 participants (Anticipated) | Interventional | 2020-10-08 | Recruiting | ||
| Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies[NCT00703625] | Phase 1 | 26 participants (Actual) | Interventional | 2008-03-08 | Completed | ||
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167] | Phase 2 | 1 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Lack of accrual and interest in study) | ||
| A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR[NCT01755923] | Phase 2 | 60 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
The phase I component of the study are to determine the safety and tolerability of pemetrexed in human subjects with non small cell lung cancer (NSCLC), and to determine the maximum tolerated dose. (NCT00923273)
Timeframe: 5 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| Treatment Level 1: 3mg Load | 500 |
| Treatment Level 2: 6mg Load | 500 |
| Treatment Level 3: 6mg Load | 500 |
| Treatment Level 4: 10mg Load | 500 |
| Treatment Level 5: 15mg Load | 500 |
The phase I component of the study are to determine the safety and tolerability of sirolimus in human subjects with non small cell lung cancer (NSCLC), and to determine the maximum tolerated dose. (NCT00923273)
Timeframe: 5 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| Treatment Level 1: 3mg Load | 10 |
| Treatment Level 2: 6mg Load | 10 |
| Treatment Level 3: 6mg Load | 10 |
| Treatment Level 4: 10mg Load | 10 |
| Treatment Level 5: 15mg Load | 10 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00923273)
Timeframe: Date treatment consent signed to date off study, approximately 45 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Subjects from phase I | 8subjects prior peme & 12 subjects peme naive | |
| Treatment Level 1: 3mg Load | 4 | 0 |
| Treatment Level 2: 6mg Load | 3 | 0 |
| Treatment Level 3: 6mg Load | 3 | 0 |
| Treatment Level 4: 10 mg Load | 7 | 20 |
| Treatment Level 5: 15mg Load | 5 | 0 |
Clinical response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is disappearance of all target lesions. Partial response (PR) at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Progressive disease (PD) is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00923273)
Timeframe: 21 weeks
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | Not evaluable | |
| Treatment Level 4: 10mg Load | 0 | 5 | 13 | 2 | 7 |
7 reviews available for ifosfamide and Disease Exacerbation
| Article | Year |
|---|---|
Perianal rhabdomyosarcoma in an adult: A case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Ifosfami | 2023 |
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Dose-Response Relati | 2017 |
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Yolk sac tumor of the bilateral basal ganglia in a patient with Down syndrome.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Basal Ganglia; Brain Neoplasms; Chemorad | 2013 |
Trilateral retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Combined Modality Thera | 2007 |
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Doxorubicin; Drug Thera | 2007 |
Second-line chemotherapy for non-small-cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung | 2000 |
60 trials available for ifosfamide and Disease Exacerbation
| Article | Year |
|---|---|
Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms | 2018 |
Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplati | 2013 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free | 2014 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; | 2015 |
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 2015 |
Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; | 2016 |
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemoradiotherapy; Cispla | 2016 |
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dise | 2009 |
Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2010 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2009 |
Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control | 2009 |
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dis | 2011 |
A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease Progression; Dose-R | 2002 |
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Dru | 2002 |
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; | 2003 |
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; C | 2003 |
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2003 |
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2003 |
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Fema | 2003 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2003 |
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Child; Child, Presch | 2004 |
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diseas | 2004 |
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Pr | 2004 |
Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; If | 2004 |
Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Disease Progression; Drug | 2005 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2006 |
Induction chemotherapy with the TIP regimen (paclitaxel/ifosfamide/cisplatin) in stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Non-Small-Cell Lung | 2006 |
Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Thera | 2006 |
Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Com | 2007 |
Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycy | 2008 |
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diseas | 1996 |
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1996 |
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carbopl | 1996 |
Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 1996 |
Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etopo | 1996 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro | 1997 |
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1997 |
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disea | 1998 |
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 1998 |
Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Dise | 1999 |
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 1999 |
A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1999 |
Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1999 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free | 2000 |
Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2000 |
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2000 |
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2001 |
Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dis | 2002 |
Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Rela | 2002 |
Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small | 2002 |
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Pro | 2002 |
Intensive chemotherapy with whole blood stem-cell support and concurrent chest radiotherapy in small cell lung cancer: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Chi | 2002 |
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Ad | 2002 |
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2002 |
51 other studies available for ifosfamide and Disease Exacerbation
| Article | Year |
|---|---|
Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Dexamethasone; Disease Progressio | 2016 |
Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 2018 |
Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Cyclophosphamide; Disease Progression; F | 2018 |
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bren | 2019 |
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Li | 2019 |
Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2019 |
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepi | 2013 |
Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Dedifferenti | 2014 |
An absolute obstacle: cardiac metastasis of synovial sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Disease Progressi | 2014 |
Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: a case report.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Ga | 2014 |
Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell | 2015 |
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modali | 2015 |
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2015 |
Pei regimen: a therapeutic option in small cell lung cancer? A retrospective monoinstitutional analysis of 46 consecutive cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Etoposide; Fem | 2015 |
Neoadjuvant chemotherapy followed by large cone resection as fertility-sparing therapy in stage IB cervical cancer.
Topics: Abortion, Missed; Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2015 |
Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brac | 2015 |
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2015 |
Germ Cell Cancer and Multiple Relapses: Toxicity and Survival.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cisplatin; Datab | 2015 |
Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cyclophosphamide; | 2008 |
A case of extranodal NK/T-cell lymphoma, nasal type mimicking typical manifestations of adult-onset Still's disease (AOSD) with hemophagocytic syndrome: diagnostic consideration between malignant lymphoma without lymphadenopathy and AOSD.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Dexamethasone | 2009 |
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control | 2009 |
Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Disease Progression; Female; Ifosfamide; Immunotherapy; I | 2009 |
[Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Etoposide; | 2009 |
CXCL13 and CXCL12 in central nervous system lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Biopsy; Cell Nucleus Shape; Chronic Disease; Disease | 2011 |
[Nephropathy following administration of angiogenesis inhibitors].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2011 |
Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free | 2011 |
Teratoid Wilms' tumor: case report of a rare variant that can mimic aggressive biology during chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dactinomycin; Disease Progression; Doxo | 2011 |
Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cispl | 2003 |
Safety of rituximab therapy during the first trimester of pregnancy: a case history.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplast | 2004 |
Pericardial synovial sarcoma: 14-year survival with multimodality therapy.
Topics: Adult; Chemotherapy, Adjuvant; Dimethoate; Disease Progression; Doxorubicin; Drug Administration Sch | 2004 |
Atypical teratoid/rhabdoid tumour with leptomeningeal dissemination in an adult.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Cisplatin; Combined Mod | 2004 |
Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Combined Modality | 2005 |
[Upper cervical chondrosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axis, Cervical Vertebra; Brachytherapy; Cervical Ver | 2005 |
Prognostic factors in pleuro-pulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, P | 2007 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2006 |
Recurrent superior mediastinal primary hemangiopericytoma 23 years after the complete initial excision: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Epirubicin; Fatal Outcome | 2006 |
Late response to radiochemotherapy in pediatric glioblastoma: report on two patients treated according to HIT-GBM protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Cisplatin; Combined Mod | 2006 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2008 |
Electrolyte abnormalities and progressive renal failure in a cancer patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; C | 2007 |
[Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
[Long-term follow-up of patients with suprasellar germinomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2007 |
Peripheral-T-cell lymphoma with hemophagocytic histiocytosis localised to the bone marrow associated with inappropriate secretion of antidiuretic hormone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Cy | 1995 |
p53 gene mutation in the bone-marrow of a patient with diffuse mixed cell type lymphoma at diagnosis predicting eventual progression to large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; Disease Progr | 1998 |
Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease Pro | 1999 |
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Div | 1999 |
[Pigmented villonodular synovitis: apropos of 3 cases].
Topics: Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Arthroplasty, Replaceme | 2001 |
Serum creatine kinase levels parallel the clinical course for rhabdomyomatous Wilms tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Creatine Kinase; Dactinomycin; Di | 2001 |